Dimethylamine

Dimethylamine

SCHEMBL2105293

CNC.Cc1cc2cc([N+](=O)[O-])ccc2o1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.54
CA9 Q16790 2/20 0.54
MAOB P27338 8/20 0.51
MAOA P21397 3/20 0.51
POLB P06746 2/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
XDH P47989 1/20 0.48
F12 P00748 1/20 0.46
MAPT P10636 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TSHR P16473 2/20 0.44
ALDH1A1 P00352 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266607 0.95 CA12 (0.57) CA12CA9MAOBMAOAPOLB
SCHEMBL8382142 0.82 CA12 (0.55) CA12CA9MAOBMAOAPOLB
SCHEMBL6597993 0.81 TSHR (0.48) CA12CA9MAPTNPC1RAB9A
SCHEMBL31415605 0.77 CA12 (0.65) CA12CA9MAOBMAOAPOLB
SCHEMBL28399285 0.76 MAOB (0.56) CA12CA9MAOBMAOAPOLB
SCHEMBL2102040 0.76 NPC1 (0.56) CA12CA9MAOBMAOAPOLB
SCHEMBL8618928 0.75 CA12 (0.55) CA12CA9MAOBMAOAPOLB
SCHEMBL17199261 0.75 MAOB (0.55) CA12CA9MAOBMAOAPOLB
SCHEMBL5177829 0.75 CA12 (0.57) CA12CA9MAOBMAOAPOLB
SCHEMBL12778676 0.75 MAOB (0.55) CA12CA9MAOBMAOAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2316459-B1 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases RIGEL PHARMACEUTICALS INC (US) 2013-11-06 EP disclosed
US-8557806-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2013-10-15 US disclosed
US-8158621-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
US-7825116-B2 -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis RIGEL PHARMACEUTICALS, INC. (US) 2010-11-02 US disclosed
US-7812029-B1 such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis RIGEL PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-7517886-B2 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS, INC. (US) 2009-04-14 US disclosed